Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

Dec 04, 2018

|

NEW YORK (GenomeWeb) – Biocartis said yesterday that it has signed a development agreement with Genomic Health to develop an in vitro diagnostic version of the Oncotype DX Genomic Prostate Score (GPS) Test.

The agreement expands on a previous partnership to develop an IVD version of Genomic Health's Oncotype DX Breast Recurrence Score test on Biocarts' Idylla platform.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Biocartis, Genomic Health to Develop IVD Version of Oncotype Prostate Test

To read the full story....

Breaking News

CDC Reverses Position, Says Asymptomatic Patients Should Be Tested for SARS-CoV-2

Roche Nabs CE Mark for SARS-CoV-2 Quantitative Antibody Test

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Mount Sinai Coronavirus Antibody Test Gets NYSDOH Emergency Use Authorization for Quantitative Use

In Brief This Week: Illumina, Siemens Healthineers, Danaher, Abbott, and More

Featured White Papers

Moving from Non-Invasive Prenatal Screening to Prenatal Diagnostics: An Expert Panel Discussion

What's Popular?

FDA Publishes First Batch of SARS-CoV-2 MDx Limit of Detection Comparison Results

FDA Grants Emergency Use Authorization to Coronavirus Tests From Visby Medical, SNIBE

Qiagen Acquires Remaining Stake in NeuMoDx Molecular for $248M

Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

Sponsorships